×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Ovarian Cancer

Feature Video
Dr Shannon Westin, a clinical investigator at the MD Anderson Cancer Center, discusses PARP inhibition for patients with deleterious or suspected deleterious germline BRCA-mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.
Katie Kosko
Although individuals may have concerns about enrolling in a study, their involvement may lead to new discoveries.
Katie Kosko
Eva Moon, a writer, musician and performing artist, discusses her genetic mutation and how it changed the direction of her life.
 
Kristie L. Kahl
In this episode of CURE Talks Cancer, we caught up with all three storytellers from the “Our Way Forward: Stories that Illuminate the Ovarian Cancer Experience,” storytelling event hosted through a special engagement with The Moth.
Jessica Skarzynski
New research indicates that aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen (Advil) or naproxen (Aleve) could not only reduce the risk of ovarian cancer, but also improve survival with daily use.
After testing positive for the BRCA mutation, Pulaski has become an advocate and authored a book titled “Mom’s Genes,” which focuses on starting the conversation with children about their family’s health history.
Brittany Lovely
Three storytellers offered their experiences with BRCA mutation at a Basser Center for BRCA event in New York City.
Kristie L. Kahl
In this special edition of the CURE Talks Cancer podcast, we kick off National Hereditary Breast and Ovarian Cancer Week and Previvor Day.
Brielle Urciuoli
Although immunotherapy’s use in ovarian cancer lags other cancer types, Matthew Powell, M.D., believes there is still promise for checkpoint blockades in this field, likely in combination with other agents.
Georgia Hurst
Seven years ago, I was diagnosed with Lynch syndrome, a hereditary cancer condition which significantly increases my chances of developing early-onset cancer.
Kelly Irvin
Researchers disagree on whether or not to monitor ovarian cancer survivors with frequent CA-125 tests. But this patient would rather have more information than less.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

Patient Caregiver Advocate Other